AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6565300 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-effect management techniques (SEMT) information
Number of subjects: 48
Study 6565300 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined drug and SEMT information
Number of subjects: 48
Study 6565300 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 31980334 — intervention group
Group type: EXPERIMENTAL
Intervention: Video and brochure intervention
Number of subjects: 551
Study 31980334 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 551
Study 31980334 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to give blood (after intervention)
Number of subjects: 551
Study 28993286 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIRIT intervention delivered by trained research nurses
Number of subjects: 400
Study 28993286 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIRIT intervention for surrogates
Number of subjects: 400
Study 28993286 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus delayed SPIRIT implementation
Number of subjects: 400
Study 27757142 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic educational program in oral health (TEPOH)
Number of subjects: 230
Study 27757142 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 230
Study 25634936 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A (SFI only)
Number of subjects: 781
Study 25634936 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B (SFI plus reminders)
Number of subjects: 781
Study 25634936 — intervention group
Group type: COMPARATOR
Intervention: Arm C (control group)
Number of subjects: 781
Study 24209657 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass practice (3 training blocks of 15 minutes each with a 5-minute break)
Number of subjects: 75
Study 24209657 — intervention group
Group type: EXPERIMENTAL
Intervention: Similar exercise (laparoscopic bean transfer)
Number of subjects: 75
Study 24209657 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissimilar exercise (open suturing)
Number of subjects: 75
Study 24209657 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation
Number of subjects: 75
Study 24209657 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest
Number of subjects: 75
Study 21911720 — intervention group
Group type: COMPARATOR
Intervention: Clonidine 0.1 mg
Number of subjects: 102
Study 21911720 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine 75 mg
Number of subjects: 102
Study 19099860 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine hydrochloride and oral rehydration salt treatment
Number of subjects: 55
Study 19099860 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration salt treatment only
Number of subjects: 55
Study 16317760 — intervention group
Group type: COMPARATOR
Intervention: IV EPO 600 IU/kg (max dose 40,000 IU) or placebo once weekly for 16 weeks, increased to 900 IU/kg (max dose 60,000 IU) if no response by week 3 or 4
Number of subjects: 12
Study 15048616 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 150 mg b.i.d. for 14 days
Number of subjects: 12
Study 15048616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11868136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (two 45-min sessions)
Number of subjects: 12
Study 11868136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 12
Study 11868136 — intervention group
Group type: COMPARATOR
Intervention: Control group (no information on OSAHS or CPAP)
Number of subjects: 12
Study 9140705 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 6
Study 9140705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 9140705 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 6
Study 7957792 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU, single oral dose)
Number of subjects: 174
Study 7957792 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 174
Study 2958383 — intervention group
Group type: EXPERIMENTAL
Intervention: CT directed biopsy
Number of subjects: 0
Study 2958383 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic directed biopsy
Number of subjects: 0
Study 2958383 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind percutaneous liver biopsy
Number of subjects: 0
Study 2958383 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 0
Study 2958383 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative CT directed biopsy
Number of subjects: 0
Study 29674251 — intervention group
Group type: EXPERIMENTAL
Intervention: NTX + BUP
Number of subjects: 378
Study 29674251 — intervention group
Group type: EXPERIMENTAL
Intervention: NTX + placebo BUP (PBO-B)
Number of subjects: 378
Study 29674251 — intervention group
Group type: COMPARATOR
Intervention: placebo NTX (PBO-N) + placebo BUP (PBO-B)
Number of subjects: 378
Study 29674251 — intervention group
Group type: EXPERIMENTAL
Intervention: NTX/BUP
Number of subjects: 378
Study 27984490 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Course (Internet-delivered cognitive behavioural pain management course)
Number of subjects: 30
Study 27984490 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 30
Study 26014940 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 11
Study 26014940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 23951825 — intervention group
Group type: EXPERIMENTAL
Intervention: Elonza (generic product of sildenafil) 100 mg taken as needed
Number of subjects: 210
Study 21914162 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (5 cups per day)
Number of subjects: 45
Study 21914162 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee (5 cups per day)
Number of subjects: 45
Study 21914162 — intervention group
Group type: COMPARATOR
Intervention: No coffee (water)
Number of subjects: 45
Study 18979392 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol
Number of subjects: 16
Study 18979392 — intervention group
Group type: COMPARATOR
Intervention: Dilapan and sulprostone
Number of subjects: 16
Study 16239897 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 14
Study 12698929 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention in the clinic waiting room
Number of subjects: 320
Study 12698929 — intervention group
Group type: COMPARATOR
Intervention: Usual clinic care (no structured education during the waiting time in the clinic)
Number of subjects: 320
Study 10636375 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal oral zidovudine
Number of subjects: 0
Study 10636375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7488485 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 3 mg kg‐1
Number of subjects: 20
Study 7488485 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone 6 mg kg‐1
Number of subjects: 20
Study 7488485 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 1827966 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg oral ondansetron
Number of subjects: 84
Study 1827966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 7302464 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of sodium aurothiomalate weekly
Number of subjects: 60
Study 7302464 — intervention group
Group type: COMPARATOR
Intervention: 50 mg of sodium aurothiomalate weekly
Number of subjects: 60
Study 29686285 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma proteins in children with small head circumference at birth
Number of subjects: 500
Study 29686285 — intervention group
Group type: COMPARATOR
Intervention: Plasma proteins in children with normal head circumference at birth
Number of subjects: 500
Study 27698559 — intervention group
Group type: EXPERIMENTAL
Intervention: TURP plus tamsulosin hydrochloride 0.2 mg (TAM)
Number of subjects: 116
Study 27698559 — intervention group
Group type: EXPERIMENTAL
Intervention: TURP plus tamsulosin hydrochloride 0.2 mg (TAM) plus solifenacin succinate 5 mg (SOL)
Number of subjects: 116
Study 27698559 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 116
Study 25936812 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed Ultra Emu Oil
Number of subjects: 45
Study 25936812 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cottonseed oil)
Number of subjects: 45
Study 23254226 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised scoring approach using a 4-point Likert response set
Number of subjects: 343
Study 23254226 — intervention group
Group type: COMPARATOR
Intervention: Original FTND scoring with forced-choice response format
Number of subjects: 343
Study 19875376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 83
Study 19875376 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 83
Study 18209516 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg)
Number of subjects: 10
Study 18209516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 16337504 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day for 12 months
Number of subjects: 43
Study 16337504 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg/day for 3 months
Number of subjects: 43
Study 16337504 — intervention group
Group type: COMPARATOR
Intervention: Lipid-lowering diet for 3 months
Number of subjects: 43
Study 14620649 — intervention group
Group type: COMPARATOR
Intervention: Counseling-only control group
Number of subjects: 140
Study 14620649 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch/bupropion group
Number of subjects: 140
Study 14620649 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch group
Number of subjects: 140
Study 14620649 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion group
Number of subjects: 140
Study 10354218 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg of TNF-alpha plus 1 mg kg-1 melphalan (IHPTM group)
Number of subjects: 9
Study 10354218 — intervention group
Group type: COMPARATOR
Intervention: 1 mg kg-1 melphalan (IHPM group)
Number of subjects: 9
Study 10354218 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IHPTM and IHPM)
Number of subjects: 9
Study 8877260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 950
Study 8877260 — intervention group
Group type: COMPARATOR
Intervention: Moderate blood pressure control
Number of subjects: 950
Study 8877260 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker (nisoldipine)
Number of subjects: 950
Study 8877260 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitor (enalapril)
Number of subjects: 950
Study 1757024 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg cefamandol administered intraocularly at the end of the operation
Number of subjects: 61
Study 1757024 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intraocularly at the end of the operation
Number of subjects: 61
Study 7113575 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide administration (CPAF test)
Number of subjects: 108
Study 7113575 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration instead of chlorpropamide
Number of subjects: 108
Study 7113575 — intervention group
Group type: EXPERIMENTAL
Intervention: Non flushers and aspecific flushers
Number of subjects: 108
Study 7113575 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure, serum lipids and hemostatic parameters
Number of subjects: 108
Study 7113575 — intervention group
Group type: EXPERIMENTAL
Intervention: Flushers
Number of subjects: 108
Study 3893308 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximate stapler
Number of subjects: 16
Study 3893308 — intervention group
Group type: COMPARATOR
Intervention: Monofilament nylon sutures
Number of subjects: 16
Study 30547820 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose stavudine (20 mg twice daily)
Number of subjects: 1067
Study 30547820 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir in combination with efavirenz and lamivudine
Number of subjects: 1067
Study 30547820 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (stavudine and tenofovir)
Number of subjects: 1067
Study 30547820 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose stavudine
Number of subjects: 1067
Study 26126817 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient palliative care (PC) visits
Number of subjects: 101
Study 26126817 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care actions
Number of subjects: 101
Study 26126817 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care for inpatients with HF
Number of subjects: 101
Study 24898574 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS over the left temporal cortex
Number of subjects: 116
Study 22269100 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression First (CF) strategy
Number of subjects: 289
Study 22269100 — intervention group
Group type: COMPARATOR
Intervention: Analyze First (AF) strategy
Number of subjects: 289
Study 20394471 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg QD for 3 weeks
Number of subjects: 241
Study 20394471 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg QD for 2 weeks
Number of subjects: 241
Study 20394471 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 500 mg QD for 4 weeks
Number of subjects: 241
Study 18065503 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected CAS (with distal filter devices)
Number of subjects: 243
Study 18065503 — intervention group
Group type: COMPARATOR
Intervention: Unprotected CAS (without distal filter devices)
Number of subjects: 243
Study 18065503 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected CAS in symptomatic patients
Number of subjects: 243
Study 18065503 — intervention group
Group type: COMPARATOR
Intervention: Unprotected CAS in symptomatic patients
Number of subjects: 243
Study 18065503 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected CAS in patients aged 75 or younger
Number of subjects: 243
Study 18065503 — intervention group
Group type: COMPARATOR
Intervention: Unprotected CAS in patients aged 75 or younger
Number of subjects: 243
Study 15515151 — intervention group
Group type: EXPERIMENTAL
Intervention: Kendall's taub as a summary measure of within-participant trends in adverse events
Number of subjects: 0
Study 15515151 — intervention group
Group type: COMPARATOR
Intervention: Repeated measures ANOVA using mixed models
Number of subjects: 0
Study 12456424 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 45
Study 12456424 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg
Number of subjects: 45
Study 12456424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 10628192 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated pancreatin (25,000 U lipase; 3 x 1 caps/day)
Number of subjects: 39
Study 10628192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 8834645 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 32
Study 8834645 — intervention group
Group type: COMPARATOR
Intervention: Nondialyzed uremic men
Number of subjects: 32
Study 8834645 — intervention group
Group type: COMPARATOR
Intervention: Healthy men
Number of subjects: 32
Study 2327823 — intervention group
Group type: EXPERIMENTAL
Intervention: AIH with native semen (N, n = 68)
Number of subjects: 172
Study 2327823 — intervention group
Group type: EXPERIMENTAL
Intervention: AIH with washed sperm (V, n = 50)
Number of subjects: 172
Study 2327823 — intervention group
Group type: EXPERIMENTAL
Intervention: AIH with semen mixed with kallikrein (K, 5 IE/ml semen, n = 45)
Number of subjects: 172
Study 2327823 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro studies with K added semen
Number of subjects: 172
Study 2327823 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary tube test (CTT) with wives' cervical mucus
Number of subjects: 172
Study 2327823 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary tube test (CTT) with donors' cervical mucus
Number of subjects: 172
Study 2327823 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall AIH program
Number of subjects: 172
Study 7017582 — intervention group
Group type: EXPERIMENTAL
Intervention: RA 27/3 rubella vaccine
Number of subjects: 502
Study 7017582 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles-mumps-rubella (RA 27/3) vaccine
Number of subjects: 502
Study 7017582 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination vaccine incorporating HPV-77:DE-5 rubella
Number of subjects: 502
Study 7017582 — intervention group
Group type: COMPARATOR
Intervention: Measles-mumps-rubella vaccines
Number of subjects: 502
Study 30744589 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-virgin olive oil Mediterranean diet
Number of subjects: 0
Study 30744589 — intervention group
Group type: COMPARATOR
Intervention: Control group without nutritional intervention
Number of subjects: 0
Study 28937894 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE tape
Number of subjects: 17
Study 28937894 — intervention group
Group type: COMPARATOR
Intervention: Cotton
Number of subjects: 17
Study 27209155 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual interruptions comprised of spatial, driving unrelated tasks
Number of subjects: 56
Study 27209155 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual interruptions comprised of non-spatial, driving unrelated tasks
Number of subjects: 56
Study 27209155 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual interruptions with no tasks added
Number of subjects: 56
Study 27209155 — intervention group
Group type: COMPARATOR
Intervention: No visual interruptions (control group)
Number of subjects: 56
Study 24440167 — intervention group
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS
Number of subjects: 420
Study 22077192 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg
Number of subjects: 15526
Study 22077192 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg
Number of subjects: 15526
Study 22077192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15526
Study 20182421 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic profiling using LC-MS on predose urine samples
Number of subjects: 29
Study 20182421 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of tacrolimus
Number of subjects: 29
Study 20182421 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial least-squares (PLS) modeling
Number of subjects: 29
Study 17959594 — intervention group
Group type: EXPERIMENTAL
Intervention: Young-isoflurane group
Number of subjects: 60
Study 17959594 — intervention group
Group type: EXPERIMENTAL
Intervention: Young-sevoflurane group
Number of subjects: 60
Study 17959594 — intervention group
Group type: COMPARATOR
Intervention: Elderly-isoflurane group
Number of subjects: 60
Study 17959594 — intervention group
Group type: COMPARATOR
Intervention: Elderly-sevoflurane group
Number of subjects: 60
Study 16389742 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug therapy
Number of subjects: 230
Study 10926129 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention intervention
Number of subjects: 46
Study 10926129 — intervention group
Group type: COMPARATOR
Intervention: Health promotion control
Number of subjects: 46
Study 9052903 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanomeline (oral formulation)
Number of subjects: 14
Study 9052903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 9052903 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanomeline (first dose)
Number of subjects: 14
Study 9052903 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanomeline
Number of subjects: 14
Study 9052903 — intervention group
Group type: EXPERIMENTAL
Intervention: Methscopolamine
Number of subjects: 14
Study 8306902 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroflumethiazide (HFM) 50mg daily
Number of subjects: 60
Study 8306902 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 80mg daily
Number of subjects: 60
Study 8306902 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 160mg daily (after 4 weeks)
Number of subjects: 60
Study 3552225 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiorinal with Codeine
Number of subjects: 0
Study 3552225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3552225 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiorinal alone
Number of subjects: 0
Study 3552225 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine alone
Number of subjects: 0
Study 30893577 — intervention group
Group type: EXPERIMENTAL
Intervention: MRA therapy (intravenous bolus of potassium canrenoate followed by oral spironolactone for 3 months)
Number of subjects: 67
Study 30893577 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for 3 months)
Number of subjects: 67
Study 30893577 — intervention group
Group type: EXPERIMENTAL
Intervention: MRA therapy
Number of subjects: 67
Study 30893577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 29183291 — intervention group
Group type: EXPERIMENTAL
Intervention: Hockey Fans in Training (Hockey FIT) program, 90-minute weekly sessions for 12 weeks followed by a 40-week minimally-supported phase.
Number of subjects: 80
Study 29183291 — intervention group
Group type: EXPERIMENTAL
Intervention: Hockey FIT program
Number of subjects: 80
Study 26085531 — intervention group
Group type: EXPERIMENTAL
Intervention: Twenty-four-hour group (received perioperative antibiotics for twenty-four hours)
Number of subjects: 314
Study 26085531 — intervention group
Group type: COMPARATOR
Intervention: Drain-duration group (received antibiotics for the duration that the drain was in place)
Number of subjects: 314
Study 23748182 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-assisted personal interviews (MPAPI)
Number of subjects: 512